21世纪治愈法案对折点与商业抗菌药物敏感性试验系统的影响:进展与不足
抗菌药物耐药是过去十年最紧迫的医学挑战,临床实验室处于准确报告抗菌药物敏感性试验结果的前线。2016年签署的21世纪治愈法案是解决阻碍商业抗菌药物敏感性试验系统开发和更新诸多监管困境的重要一步。本文描述了美国对商业抗菌药物敏感性试验系统监管的路径和历史,并概述了21世纪治愈法案可能带来的收益和未满足的需求。
要点
- 抗菌药物耐药是紧迫的医学挑战,临床实验室负责准确报告药敏结果。
- 实验室检测耐药的能力受到多种因素阻碍。
- 21世纪治愈法案旨在解决商业药敏系统开发和更新的监管困境。
核心结论
- 21世纪治愈法案是解决阻碍商业抗菌药物敏感性试验系统开发和更新监管困境的重要一步。
研究设计与样本
- 本文为综述,描述美国对商业抗菌药物敏感性试验系统监管的路径和历史,并概述21世纪治愈法案的收益与未满足需求。
主要发现
- 实验室检测耐药的能力受到多种因素阻碍。
- 21世纪治愈法案可能带来收益,但仍存在未满足的需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimicrobial resistance is the most pressing medical challenge of the past decade. At the front line are clinical laboratories, which are responsible for accurately reporting antimicrobial susceptibility test (AST) results to clinicians and public health authorities. The ability of the laboratory to detect resistance has been hampered by several factors. In 2016, the 21st Century Cures Act was signed into law, marking an important step toward resolving many regulatory dilemmas that hampered development and updates to commercial AST systems (cASTs). We describe the pathway and history of U.S. regulation of cASTs and outline both the rewards and unmet needs possible from the 21st Century Cures Act.
引用
- Humphries RM, Ferraro MJ, Hindler JA, et al. Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls. J Clin Microbiol. 2018. PMID: 29436415. doi:10.1128/JCM.00139-18
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。